

Recombinant Human PD-L1/B7-H1/CD274 Protein (ECD, Fc Tag)

Catalog No. PKSH030444

Note: Centrifuge before opening to ensure complete recovery of vial contents.


Description

Synonyms	Programmed Cell Death 1 Ligand 1;PD-L1;PDCD1 ligand 1;Programmed death ligand 1;B7 homolog 1;B7-H1;CD274;B7H1;PDCD1L1;PDCD1LG1;PDL1
Species	Human
Expression Host	HEK293 Cells
Sequence	Met 1-Thr 239
Accession	NP_054862.1
Calculated Molecular Weight	51.7 kDa
Tag	C-mFc
Bioactivity	Measured by its ability to inhibit anti-CD3 antibody induced IFN γ secretion in human T lymphocytes. The ED50 for this effect is 2-10 μ g/mL.

Properties

Purity	> 95 % as determined by reducing SDS-PAGE.
Endotoxin	< 1.0 EU per μ g of the protein as determined by the LAL method.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Formulation	Lyophilized from sterile PBS, pH 7.4 Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween80 are added as protectants before lyophilization. Please refer to the specific buffer information in the printed manual.
Reconstitution	Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Programmed death-1 ligand-1 (PD-L1; CD274; B7-H1) has been identified as the ligand for the immunoinhibitory

For Research Use Only

receptor programmed death-1(PD1/PDCD1) and has been demonstrated to play a role in the regulation of immune responses and peripheral tolerance. PD-L1/B7-H1 is a member of the growing B7 family of immune molecules and this protein contains one V-like and one C-like Ig domain within the extracellular domain; and together with PD-L2; are two ligands for PD1 which belongs to the CD28/CTLA4 family expressed on activated lymphoid cells. By binding to PD1 on activated T-cells and B-cells; PD-L1 may inhibit ongoing T-cell responses by inducing apoptosis and arresting cell-cycle progression. Accordingly; it leads to growth of immunogenic tumor growth by increasing apoptosis of antigen specific T cells and may contribute to immune evasion by cancers. PD-L1 thus is regarded as promising therapeutic target for human autoimmune disease and malignant cancers.